Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

URGN – UroGen Pharma Ltd.

Float Short %

17.74

Margin Of Safety %

Put/Call OI Ratio

0.42

EPS Next Q Diff

EPS Last/This Y

-0.03

EPS This/Next Y

1.66

Price

18.79

Target Price

33.75

Analyst Recom

1.25

Performance Q

69.58

Relative Volume

0.41

Beta

1.02

Ticker: URGN




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-08-15URGN19.740.380.3440188
2025-08-18URGN19.390.370.9728859
2025-08-19URGN18.90.370.4129306
2025-08-20URGN19.330.370.1029327
2025-08-21URGN19.770.370.0629463
2025-08-22URGN19.410.370.3429422
2025-08-25URGN18.480.370.8029441
2025-08-26URGN19.50.380.1229536
2025-08-27URGN19.50.380.0029607
2025-08-28URGN19.240.380.5629611
2025-08-29URGN19.450.380.0129677
2025-09-02URGN19.50.370.0730395
2025-09-03URGN19.350.370.7730365
2025-09-04URGN18.80.380.4230945
2025-09-05URGN18.880.380.0031000
2025-09-08URGN21.540.380.0331053
2025-09-09URGN20.690.373.6031939
2025-09-10URGN19.10.391.1232308
2025-09-11URGN19.250.408.9532898
2025-09-12URGN18.780.420.1833325
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-08-15URGN19.71-12.1- -2.96
2025-08-18URGN19.40-12.1- -2.96
2025-08-19URGN18.92-12.1- -2.96
2025-08-20URGN19.30-12.1- -2.96
2025-08-21URGN19.77-12.1- -2.96
2025-08-22URGN19.41-14.0- -2.99
2025-08-25URGN18.50-14.0- -2.99
2025-08-26URGN19.50-14.0- -2.99
2025-08-27URGN19.52-14.0- -2.99
2025-08-28URGN19.24-14.0- -2.99
2025-08-29URGN19.43-14.0- -2.99
2025-09-02URGN19.52-14.0- -2.99
2025-09-03URGN19.36-14.0- -2.99
2025-09-04URGN18.80-14.0- -2.99
2025-09-05URGN18.88-14.0- -2.99
2025-09-08URGN21.42-14.0- -2.99
2025-09-09URGN20.69-14.0- -2.99
2025-09-10URGN19.12-14.0- -2.99
2025-09-11URGN19.25-14.0- -2.99
2025-09-12URGN18.79-14.0- -2.99
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-08-15URGN-0.4331.5718.03
2025-08-18URGN-0.4342.6918.12
2025-08-19URGN-0.4142.6918.12
2025-08-20URGN-0.4142.6918.12
2025-08-21URGN-0.4142.6918.12
2025-08-22URGN-0.4142.6918.12
2025-08-25URGN-0.41-0.7018.12
2025-08-26URGN-0.41-0.7018.12
2025-08-27URGN-0.41-0.7017.37
2025-08-28URGN-0.41-0.7017.37
2025-08-29URGN-0.41-0.7017.37
2025-09-02URGN-0.41-0.6917.37
2025-09-03URGN-0.41-0.6917.37
2025-09-04URGN-0.41-0.6917.37
2025-09-05URGN-0.41-0.6917.37
2025-09-08URGN-0.41-0.6917.37
2025-09-09URGN-0.41-0.6917.37
2025-09-10URGN-0.45-0.6917.37
2025-09-11URGN-0.45-0.6917.74
2025-09-12URGN-0.45-0.6917.74
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

-0.63

Avg. EPS Est. Next Quarter

-0.39

Insider Transactions

-0.45

Institutional Transactions

-0.69

Beta

1.02

Average Sales Estimate Current Quarter

34

Average Sales Estimate Next Quarter

44

Fair Value

Quality Score

24

Growth Score

49

Sentiment Score

69

Actual DrawDown %

33.4

Max Drawdown 5-Year %

-85.4

Target Price

33.75

P/E

Forward P/E

PEG

P/S

9.22

P/B

P/Free Cash Flow

EPS

-3.32

Average EPS Est. Cur. Y​

-2.99

EPS Next Y. (Est.)

-1.33

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-164.44

Relative Volume

0.41

Return on Equity vs Sector %

273.1

Return on Equity vs Industry %

286.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.11

EBIT Estimation

UroGen Pharma Ltd.
Sector: Healthcare
Industry: Biotechnology
Employees: 253
UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301, UGN-301+ UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.
stock quote shares URGN – UroGen Pharma Ltd. Stock Price stock today
news today URGN – UroGen Pharma Ltd. stock forecast ,stock prediction 2023 2024 2025
marketwatch URGN – UroGen Pharma Ltd. yahoo finance google finance
stock history URGN – UroGen Pharma Ltd. invest stock market
stock prices URGN premarket after hours
ticker URGN fair value insiders trading